Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical Cancer

Summary

Patients with recurrent or metastatic cervical cancer，and will be treated with GLS-010.

Timeline

Start

2019-05-15

Primary completion

2022-05-15

Completion

2023-05-15

Publications

• Xia L, Wang J, Wang C, Zhang Q, Zhu J, Rao Q, Cheng H, Liu Z, Yin Y, Ai X, Gulina K, Zheng H, Luo X, Chang B, Li L, Liu H, Li Y, Lou G, Zhou Q, Zhu Y, Xiao Z, Tong J, Wang K, Chen J, Wang X, Song L, Wei Z, Ye Y, Zhu J, Wu X. Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II study. Int J Gynecol Cancer. 2023 Dec 4;33(12):1861-1868. doi: 10.1136/ijgc-2023-004705.

Drugs

Indications